HOYA announced the sale of its US vitreous surgery subsidiary, MID Labs, to Bausch + Lomb. The deal is part of a portfolio review to concentrate resources on core businesses, with minimal impact on current consolidated earnings.
HOYA will transfer all shares of Medical Instrument Development Laboratories, Inc. (MID Labs), based in California, to Bausch + Lomb Corporation. MID Labs was established in 1981 and manufactures vitreous surgery instruments. It is a wholly owned subsidiary with capital of 146 million USD. The buyer, Bausch + Lomb, is headquartered in Vancouver, Ontario, and focuses on eye care products like contact lenses and intraocular lenses. Parent company Bausch Health Companies Inc. holds approximately 88% of its shares. A transaction relationship already exists through HOYA's "ICL" eye care chain selling Bausch + Lomb lenses. HOYA will divest 3,648,539 shares, reducing its voting rights from 100% to 0%. The closing date is set for November 2, 2026, following the contract signing on October 9, 2026.
To enhance corporate value, HOYA continuously reviews its business portfolio in response to environmental changes. This decision represents a critical step in optimizing resource allocation.
A comparison of recent financial data reveals significant scale differences between the two companies. For the fiscal year ending March 2026, MID Labs reported revenue of 34 million USD and a net income attributable to parent shareholders of 5 million USD. Total assets stood at 125 million USD and equity at 113 million USD. Revenue has shown a downward trend from 42 million USD in the fiscal year ending March 2024, following a loss of -1 million USD in FY2025, but it has returned to profitability this period.
In contrast, Bausch + Lomb operates on a much larger scale, with revenue of 5.1 billion USD and total assets of 14 billion USD for the fiscal year ending December 2025. Operating income remains steady at 200 million USD, providing ample infrastructure to absorb and nurture MID Labs' earnings. This suggests that HOYA's divested unit may be reorganized within a larger entity enjoying greater scale economies.
MID Labs revenue of 34 million USD is limited in the context of HOYA's consolidated performance, avoiding direct financial shock from the divestment. This move is interpreted as exiting a business with diminishing growth prospects to reallocate resources to other areas.
HOYA explicitly stated that the impact of this subsidiary transfer on its current consolidated earnings will be minimal. This implies that impairment losses from deconsolidation or gains/losses from the sale will not distort current results, offering reassurance to investors. Given past periods of deficit for MID Labs, it is highly likely that the sale was completed at a profitable or fair price.
HOYA has previously signaled a strategic review of the vitreous surgery market, moving away from in-house manufacturing and sales toward specialization in core areas. This transfer to Bausch + Lomb should be viewed not merely as an asset sale but as outsourcing to an optimal partner within industry restructuring trends. Considering relationships with competitors and related manufacturers, this will likely contribute to overall efficiency in the eye care market.
The focus now shifts to how HOYA allocates the divested resources to new fields or existing core business expansion. While short-term stock price impact is limited, the market calmly evaluates this as the first step toward long-term portfolio refreshment.
Analyst take
This disclosure marks HOYA's strategic withdrawal from certain US medical device segments to concentrate resources on growth areas. The selection of Bausch + Lomb, an industry leader, allows MID Labs' technology and customer base to thrive within a larger organization. This is seen as a rational decision aimed at maximizing operational efficiency. Investors should focus on expectations for balance sheet improvement and the effective use of resulting cash flow. Since the impact on current earnings is minimal, this is likely to be viewed positively as a medium-to-long-term corporate value driver rather than a short-term negative factor.
__Key next points include HOYA's priority investment areas and the disclosure of proceeds usage, if any.==
